OTCMKTS:GNHAF - Vifor Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$144.19
+0.30 (1.20%)

This chart shows the closing price for GNHAF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vifor Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNHAF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNHAF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Vifor Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $144.19.

This chart shows the closing price for GNHAF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Vifor Pharma.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/1/2021UBS GroupUpgradeSell ➝ Neutral
2/10/2021BarclaysReiterated RatingEqual Weight
1/22/2021UBS GroupDowngradeNeutral ➝ Sell
1/4/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
10/22/2020Credit Suisse GroupReiterated RatingOutperform
10/21/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/21/2020UBS GroupReiterated RatingNeutral
9/4/2020Stifel NicolausReiterated RatingBuy
9/2/2020BarclaysReiterated RatingEqual Weight
8/26/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
8/13/2020UBS GroupReiterated RatingNeutral
8/12/2020Credit Suisse GroupReiterated RatingOutperform
4/16/2020UBS GroupUpgradeSell ➝ Neutral
(Data available from 6/24/2016 forward)
Vifor Pharma logo
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.
Read More

Today's Range

Now: $144.19
Low: $144.19
High: $144.19

50 Day Range

MA: $142.16
Low: $139.36
High: $144.19

52 Week Range

Now: $144.19
Low: $125.38
High: $149.99

Volume

N/A

Average Volume

213 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vifor Pharma?

The following Wall Street research analysts have issued stock ratings on Vifor Pharma in the last twelve months: Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Stifel Nicolaus, and UBS Group AG.
View the latest analyst ratings for GNHAF.

What is the current price target for Vifor Pharma?

0 Wall Street analysts have set twelve-month price targets for Vifor Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Vifor Pharma in the next year.
View the latest price targets for GNHAF.

What is the current consensus analyst rating for Vifor Pharma?

Vifor Pharma currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GNHAF, but not buy more shares or sell existing shares.
View the latest ratings for GNHAF.

What other companies compete with Vifor Pharma?

How do I contact Vifor Pharma's investor relations team?

The company's listed phone number is 41 58 851 80 00. The official website for Vifor Pharma is www.viforpharma.com.